skip to content

Cambridge Academy of Therapeutic Sciences

 

Our Industry Experts in Residence are available to University of Cambridge staff for:

  • Advice on the applicability of specific ideas to drug discovery, diagnostics & devices

  • Advice on translational grant applications

  • Discussions about progression of current translational research projects

  • Work in conjunction with Cambridge Enterprise

They each visit the University on a regular basis throughout the year and we can work with you to find a suitable date, time and location for your meeting.

If you have an idea or problem relating to research translation that you would like to discuss with any of our Industry Experts in Residence, please contact us on CATS@admin.cam.ac.uk

01223 766163


Dr Jeremy Griggs, GSK
Drug Discovery and Development

Jeremy has extensive knowledge of the drug discovery process, with over fifteen years of experience in the pharmaceutical industry following obtaining his PhD from the University of Cambridge. His particular specialisms include biopharmaceuticals and oncology. His current interests focus on innovative approaches to drug discovery which are based on partnerships between biotechnology, academic and industrial sectors.

Talk to Jeremy about:

  • Oncology & biopharmaceuticals
  • Drug discovery processes & industrial perspective for novel therapeutics
  • Defining critical pre-clinical studies to strengthen project proposals

View Jeremy's LinkedIn profile for more details


Dr John Pritchard, Consultant
Diagnostics, Devices & Biotechnology

John has a wealth of knowledge in the field of diagnostics and devices. He has experience of managing technology start-ups, state-of-the-art operations, cross-functional teams, IP assets and organisational expansion projects to achieve competitive market advantages.  He is a recognised industry pioneer with over 30 years of industrial experience, including advisory roles and board level experience. 

Talk to John about:

  • Development of diagnostics & devices
  • Technology evaluation & acquisition
  • Market assessment, spin outs & licensing

View John's LinkedIn profile for more details


Dr Tim Allsopp, Consultant
Stem Cells & Gene Therapy

Tim has extensive industrial experience in commercial and clinical translation of stem cell science, extensive knowledge of the international cell therapies sector and product development experience from stints in both biotech and big pharma. As a company CSO he was instrumental in the growth from start up to public market listing of a pioneering stem cell biotech and he acts as subject matter specialist in evaluating technology for internationally funded, public sector and charity supported regenerative medicine programmes.

Talk to Tim about:

  • Human stem cell technologies
  • Strategic partnerships with industry
  • Development of small & medium enterprises

View Tim's LinkedIn profile for more details


Dr Claire Thompson, Consultant
Pharmaceutical Product Development

Claire has more than 15 years’ experience in the Pharmaceutical Industry spanning the large multi-nationals GlaxoSmithKline and Pfizer, virtual and Contract Research Organisations. Having taken a range of therapeutic products through clinical Phases 1 to 3, she thrives on translating innovative technologies into healthcare products and shaping technical and organisational strategies.

Talk to Claire about:

  • Pharmaceutical product development and commercialization
  • Business planning
  • Communicating science with impact

View Claire's LinkedIn profile for more details


Dr Jon Lyon, GSK
Medicines Safety

Jon is an investigative toxicologist with extensive knowledge of the drug discovery and development process with over 20 years of experience in the pharmaceutical industry after obtaining a PhD from Imperial College, London.  His specialist area is mitochondria and bioenergetics and he leads GSK’s Mitochondrial Network and has collaborations with academia including Cambridge.

Talk to Jon about:

  • Mitochondrial dysfunction in disease states and drug-induced toxicity
  • Application of technologies in drug discovery and development
  • Support for grant applications

This initiative is supported by a grant from the Medical Research Council – Proximity to Discovery: Industry Engagement Fund